New light adjustable lenses results

Article

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

The LAL allows the doctor to adjust and refine the refraction following implantation using a Vision Light Delivery device, which is an ultra light system. Doctors are able to set the refractive correction to suit the specific visual needs of their patient prior to undertaking the final procedure to set the correction.

Published in the May issue of the Journal of Refractive Surgery the Klinik und Poliklinik für Augenheilkunde in Munich, Germany the initial results, at two weeks postoperatively, before the first light adjustment was made the mean refraction was +0.78 D, ±0.79 D. After the initial adjustment, the mean refraction improved to -0.07 D, ±0.21 D. Four eyes were treated with a second adjustment. At 1 month postoperative, all eyes were within ±0.50 D of the targeted refraction, with a mean uncorrected distance visual acuity of 1.02. All eyes gaining at least two lines of corrected distance visual acuity.

Results presented at ARVOA poster, which was presented by the Optics Laboratory of the University of Murcia and the Department of Ophthalmology at the University Hospital, Virgen de la Arrixaca, Murcia, Spain, at the recent ARVO meeting reported on monovision and asphericity results in patients implanted bilaterally with the LAL. In the monovision study, 8 patients had one eye adjusted for emmetropia with the fellow eye adjusted for myopia. The final mean refraction in the emmetropia eyes ranged from 0.00D to -0.75 D, and in the myopic eyes from -1.75 D to -2.25 D. The researchers pointed out that with the LAL, if a patient could not tolerate monovision, then the treatment could be reversed in the myopic eye and set to emmetropia – something that cannot be done with a non-adjustable IOL.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.